A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
167
Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).
University of Colorado
Denver, Colorado, United States
RECRUITINGCHI Health Research Center
Omaha, Nebraska, United States
RECRUITINGProvocative pad weight
Change in provocative pad weight from baseline
Time frame: 12 months
Urogenital Distress Inventory (UDI)
Six item questionnaire. Scores range from 0-100. 0 being not distressed, 100 being very distressed.
Time frame: 12 months
Incontinence Quality of Life Questionnaire (I-QOL)
Twenty-two item questionnaire. Scores range from 0-100. 0 being lowest quality of life, 100 being highest quality of life.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.